For Your Society

Whiskey & Immigrants is our new podcast which introduces listeners to regular, everyday people who have immigrated to the U.S. from elsewhere.

We’ll learn about their country of origin, how and why they came to here, find out how their expectations of the U.S. square with the reality they’ve encountered, politics, food, history and and so much more.

Join us.

Episodes now available:

  • S01E01 – Mexico – Santiago Sanchez
  • S01E02 – Slovenia – Gregor Strakl

Subscribe now on iTunes!

Whiskey & Immigrants is our new podcast which introduces listeners to regular, everyday immigrants. We hear their stories, how and why they came to America, their expectations vs. reality and much more. We hope you’ll join us.

Subscribe now on iTunes

you'd share this if you knew what was good for you

Will antibodies finally put an end to migraines?

Update: Yesterday, 17 March, the U.S. Food and Drug Administration approved the first in a new class of drugs designed to prevent migraines. This feature, originally published on 7 January 2016, describes the history of these drugs, the powerful relief they can bring some patients, and the limitations that still exist with them.

As long as she can remember, 53-year-old Rosa Sundquist has tallied the number of days per month when her head explodes with pain. The migraines started in childhood and have gotten worse as she’s grown older. Since 2008, they have incapacitated her at least 15 days per month, year-round.

Head-splitting pain isn’t the worst of Sundquist’s symptoms. Nausea, vomiting, and an intense sensitivity to light, sound, and smell make it impossible for her to work—she used to be an office manager—or often even to leave her light-proofed home in Dumfries, Virginia. On the rare occasions when she does go out to dinner or a movie with her husband and two college-aged children, she wears sunglasses and noise-canceling headphones. A short trip to the grocery store can turn into a full-blown attack “on a dime,” she says.

Every 10 weeks, Sundquist gets 32 bee sting–like injections of the nerve-numbing botulism toxin into her face and neck. She also visits a neurologist in Philadelphia, Pennsylvania, who gives her a continuous intravenous infusion of the anesthetic lidocaine over 7 days. The lidocaine makes Sundquist hallucinate, but it can reduce her attacks, she says—she recently counted 20 migraine days per month instead of 30. Sundquist can also sometimes ward off an attack with triptans, the only drugs specifically designed to interrupt migraines after they start.

Millions of others similarly dread the onset of a migraine, although many are not afflicted as severely as Sundquist. Worldwide, migraines strike roughly 12% of people at least once per year, with women roughly three times as likely as men to have an attack. The Migraine Research Foundation estimates that U.S. employees take 113 million sick days per year because of migraines, creating an annual loss of $13 billion. The toll underscores how little current treatments—not just drugs, but nerve-numbing injections, behavioral therapies, and special diets—can help many people. 

On the horizon, however, is a new class of drugs that many scientists believe can stop migraines at their root. The drugs block the activity of a molecule called calcitonin gene-related peptide, or CGRP, which spikes during migraine

FOR YOUR SOCIETY

RELATED STORIES:

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Menu